about us

 

Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease. The Company’s proprietary product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis. In addition, Pulmatrix is pursuing opportunities in major pulmonary diseases through collaboration with partners, including PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease.

 

Pulmatrix Profile – Health and Science Report

 

Pulmatrix’s iSPERSE™: An Engineered Solution to Effectively Treat Respiratory Diseases

 

 

Recent News
AAA8 – 2018 – Efficacy of PUR1900, An Inhaled Antifungal Therapy, in a Guinea Pig Model of Invasive Pulmonary Aspergillosis / PDF
Nov 29, 2018

Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced that it has entered into a securities purchase agreement with an institutional investor, providing...

Nov 21, 2018

Pulmatrix, Inc. (NASDAQ: PULM) announced the results of the completed first-in-human study of Pulmazole (PUR1900) — an inhaled iSPERSETM formulation of the anti-fungal drug itraconazole for the...

Nov 15, 2018

Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases will present the results of the recently...

Events
Monday, January 11, 2016
5:30pm - 6:00pm EST
Wednesday, March 9, 2016
11:20am - 11:50am EST

print email
 
 
© 2015 Pulmatrix, Inc. All Rights Reservedhome   about pulmatrix   platform   pipeline   investors   careers   contact   site design